Artiva Biotherapeutics (ARTV) stock surged on Friday after the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to the clinical-stage biotechnology company’s AlloNK with rituximab for the treatment of refractory rheumatoid arthritis (RA). Refractory RA is a type of arthritis that doesn’t respond to standard treatment methods and causes persistent joint or systemic inflammation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Artiva Biotherapeutics has provided details about what it will do next with the development of AlloNK. The company plans to share patient safety data in November. Following that, it expects to release clinical response data from more than 15 refractory RA patients in the first half of 2026. In that same window of time, it also expects to conduct regulatory interactions with the FDA.
Artiva Biotherapeutics CEO Fred Aslan said, “We are prioritizing refractory RA as our lead autoimmune indication for AlloNK given the size of this underserved population. Despite the many approved therapies in RA, there are over 100,000 patients in the United States who remain treatment refractory and could potentially benefit from a deep B-cell depleting therapy.”
Artiva Biotherapeutics Stock Movement Today
Artiva Biotherapeutics stock was up 105.05% in pre-market trading on Friday, following a 7.97% drop yesterday. The shares have fallen 72.52% year-to-date and 77.24% over the past 12 months.
Today’s news resulted in heavy trading of ARTV stock, with more than 28.5 million shares traded as of this writing. That’s well above the company’s three-month daily average of about 87,000 units.
Is Artiva Biotherapeutics Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Artiva Biotherapeutics is Strong Buy, based on five Buy ratings over the past three months. With that comes an average ARTV stock price target of $14.50, representing a potential 423.47% upside for the shares.
